About VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales242.69
Price / CashN/A
Book Value$1.88 per share
Price / Book1.73
EPS (Most Recent Fiscal Year)N/A
Return on Equity-47.54%
Return on Assets-36.98%
VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
How were VBI Vaccines' earnings last quarter?
VBI Vaccines (NASDAQ:VBIV) issued its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biopharmaceutical company had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.21 million. VBI Vaccines had a negative return on equity of 47.54% and a negative net margin of 4,607.13%. View VBI Vaccines' Earnings History.
What price target have analysts set for VBIV?
3 equities research analysts have issued 12 month target prices for VBI Vaccines' stock. Their forecasts range from $10.00 to $13.00. On average, they expect VBI Vaccines' stock price to reach $11.50 in the next twelve months. View Analyst Ratings for VBI Vaccines.
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals Cl A (KNSA), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Dova Pharmaceuticals (DOVA), AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), CymaBay Therapeutics (CBAY), NuCana (NCNA), ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), Inflarx (IFRX), Urogen Pharma (URGN) and Vectura Group (VEGPF).
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)
- Dr. David Evander Anderson, Chief Scientific Officer (Age 48)
- Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 63)
- Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 53)
- Ms. Nell Beattie, Chief Bus. Officer (Age 30)
Has VBI Vaccines been receiving favorable news coverage?
News headlines about VBIV stock have been trending somewhat positive on Monday, according to Accern. The research group scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. VBI Vaccines earned a daily sentiment score of 0.05 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.46 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are VBI Vaccines' major shareholders?
VBI Vaccines' stock is owned by a number of of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (4.23%), Cambridge Investment Research Advisors Inc. (2.17%), Sphera Funds Management LTD. (1.04%) and Russell Investments Group Ltd. (0.77%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Institutional Ownership Trends for VBI Vaccines.
Which institutional investors are selling VBI Vaccines stock?
Which institutional investors are buying VBI Vaccines stock?
VBIV stock was acquired by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD. and Russell Investments Group Ltd.. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Opko Health, Inc, Perceptive Advisors Llc and Steven Gillis. View Insider Buying and Selling for VBI Vaccines.
How do I buy shares of VBI Vaccines?
Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBIV stock can currently be purchased for approximately $3.25.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of $226.04 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe.
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]
MarketBeat Community Rating for VBI Vaccines (VBIV)MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.